ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. The company is headquartered in Shanghai, Shanghai and currently employs 195 full-time employees. The company went IPO on 2023-09-05. The firm's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The firm's core product IMM01 is an innovative CD47-targeted molecule. The firm mainly operates its businesses in the domestic and overseas markets.
01541.HK stock price ended at $5.88 on 星期一, after dropping 5.62%
On the latest trading day Jan 19, 2026, the stock price of 01541.HK fell by 5.62%, dropping from $6.23 to $5.88. During the session, the stock saw a volatility of 7.41%, with prices oscillating between a daily low of $5.80 and a high of $6.23. On the latest trading day, the trading volume for 01541.HK rose by 428.8K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.6M shares were traded, with a market value of approximately $2.4B.